Pyrilutamide (KX-826) is a new treatment for hair loss. It is currently in a phase II trial and appears to be promising. It works by blocking DHT function. It is manufactured by Kintor Pharmaceuticals and is available online.
KX-826 is a chemical developed by Suzhou Kintor Pharmaceuticals. It is undergoing phase II clinical trials for androgenic alopecia in China and the U.S. It has a similar structure to RU58841.
It is a potential first-in-class small molecule AR antagonist
Buy pyrilutamide Europe is a new and promising treatment for androgenic alopecia (AGA) and acne vulgaris. It is the first AR antagonist to reach phase III clinical trials and is currently being tested in male patients in the US and China. It also has a good safety profile. The company behind this treatment, Kintor Pharmaceutical, develops innovative treatments for androgen receptor-related diseases that have unmet medical needs.
The three-dimensional structure of the AR ligand binding domain (LBD) makes it an attractive target for drug discovery. This has led to a class of drugs called antiandrogens, which compete with androgens for the LBD, preventing it from binding DNA and inducing transcriptional activity. However, resistance to these drugs is common and a new strategy is needed. A new study has identified a pocket on the AR dimer interface pocket (DIP), which is distinct from the LBD and can be targeted with small molecules. The lead compound, M17-B15, shows remarkable anti-PCa efficacy in in vitro and mouse xenograft models.
It is a promising topical treatment for alopecia
Currently, effective treatment options for alopecia are limited to two drugs: topical minoxidil and oral finasteride. Pyrilutamide, a first-in-class small molecule AR antagonist developed by Kintor Pharmaceuticals, could become a third option. It is being tested in a phase II clinical trial for androgenetic alopecia.
The phase I clinical trial for pyrilutamide was a double-blind, placebo-controlled, parallel-group, dose-escalation study that evaluated the safety and tolerability of the drug in healthy male subjects with androgenetic alopecia. The drug demonstrated low blood concentrations and good scalp tolerance with multiple ascending dose administration.
Kintor Pharmaceuticals is developing other Janus kinase (JAK) inhibitors for treating alopecia areata and other diseases. The company is also evaluating its lead product candidate GT20029, a potent JAK inhibitor that has shown promising activity in rheumatoid arthritis and inflammatory bowel disease. It also shows promise in psoriasis, vitiligo, and other skin conditions. The company is expected to submit its data for approval in 2021.
It is manufactured by Kintor Pharmaceuticals
The company has been included in the Shanghai-Hong Kong Stock Connect program, which increases its liquidity and market influence in the mainland capital markets. It has also been selected as a “2022 Gusu Innovation and Entrepreneurship Leading Talent”.
Kintor Pharmaceuticals is a clinical-stage novel drug developer in China focused on the research and development of drugs for cancers and other AR-related diseases. Its lead drug candidate is Pruxelutamide, which is undergoing phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). Kintor Pharma’s pipeline includes seven drug candidates, including Pyrilutamide, ALK-1, Detorsertib, and a hedgehog signal translation inhibitor GT1708F.
Buy pyrilutamide in Europe is manufactured in Suzhou, China by Kintor Pharmaceuticals. The 0.5% solution is stored in an air and light tight bottle and should be kept in a cool environment. Each batch of raw material is tested and confirmed to be >99% pure by a professional testing lab. GlobalData provides indication benchmark PTSR and LoA scores for Phase II drugs using proprietary data and analytics, which are built off 18 years of drug development history.
It is available online
Pyrilutamide (also known as KX-826) is the highest potency topical AR antagonist currently available. It has been shown to be a powerful alternative to finasteride and dutasteride for treating hair loss. It also has a unique mechanism of action against DHT, which is the main cause of hair loss in men. It is available in the form of a 0.5% solution. All bottles are shipped with a plastic 1ml pipette for accurate measurements.
PyriPure is a high purity formulation of pyrilutamide in a propylene glycol and ethanol vehicle. The raw material pyrilutamide (KX-826) used for this formulation was confirmed to be >99% pure by a 3rd party testing lab. The product maintains potency for at least two years after mixing.
Kintor Pharmaceutical is planning to conduct larger scale, phase III trials of pyrilutamide in 2022 for androgenic alopecia. GlobalData has created drug-specific PTSR and LoA benchmarks for this indication based on 18 years of historical data. These are available in the Pyrilutamide PTSR LoA Report.